Biogen acquires RayThera in deal worth up to $1 billion
Biogen acquires RayThera in deal worth up to $1 billion.
RayThera
Private
RayThera is a San Diego-based private biotech developing small-molecule therapeutics in immunology. Founded in 2023 with a $110M Series A, the company is being acquired by Biogen in a deal worth up to $1B, marking a major exit for the immunology-focused startup.
Company Info
Sector:Biotechnology / Immunology (Small Molecule)
Headquarters:San Diego, California, USA
Founded:2023
Website:www.raythera.com/
Funding Round:Series A ($110M, April 2025)
Total Funding:$110M reported prior to acquisition
Funding & Investor Relations
Notable Investors
- Atlas Venture
- RA Capital
- BVF Partners
- OrbiMed
- Surveyor Capital
IPO Outlook / Plans
Acquired by Biogen (June 2026)
Upcoming Milestones & Key Dates
2026-06-17
M&A
Biogen acquisition announced (up to $1B)
2026-Q3
M&A
Expected acquisition close
2027
Regulatory
Lead asset IND filing target
Clinical Development Pipeline
Undisclosed lead immunology asset
Target: Small moleculeUndisclosed second program
Target: Small moleculeExploratory programs
Target: Small moleculeRecent News
Leadership Team
Mary Gieson
VP Corporate Operations
Founder team
Scientific founders (small-molecule immunology)
Biogen integration lead
Post-acquisition integration
Careers & Job Openings